BioLineRx (BLRX) Payables (2021 - 2025)

BioLineRx has reported Payables over the past 5 years, most recently at $3.5 million for Q4 2025.

  • Quarterly results put Payables at $3.5 million for Q4 2025, down 37.44% from a year ago — trailing twelve months through Dec 2025 was $3.5 million (down 37.44% YoY), and the annual figure for FY2025 was $3.5 million, down 37.44%.
  • Payables for Q4 2025 was $3.5 million at BioLineRx, down from $5.6 million in the prior quarter.
  • Over the last five years, Payables for BLRX hit a ceiling of $10.9 million in Q4 2023 and a floor of $3.5 million in Q4 2025.
  • Median Payables over the past 5 years was $5.6 million (2024), compared with a mean of $6.5 million.
  • Biggest five-year swings in Payables: surged 56.03% in 2023 and later tumbled 48.63% in 2024.
  • BioLineRx's Payables stood at $5.6 million in 2021, then rose by 25.13% to $7.0 million in 2022, then surged by 56.03% to $10.9 million in 2023, then crashed by 48.63% to $5.6 million in 2024, then tumbled by 37.44% to $3.5 million in 2025.
  • The last three reported values for Payables were $3.5 million (Q4 2025), $5.6 million (Q4 2024), and $10.9 million (Q4 2023) per Business Quant data.